Search filters
Filters
Clear All

Phase

  • 1
  • 4
  • 3
  • 1
  • 55
  • 66
  • 60
  • 1
  • 1
  • 64

Found 66 Metastatic Cancer trials

A listing of Metastatic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 24922 First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors

99 or below
All genders
Please refer to Protocol Section 5 (Trial Objectives) Please refer to Protocol 6.2.1 (Phase 1 Primary Endpoints) and Protocol Section 6.2.4 (Phase 2 Primary Endpoints) Please refer to Protocol 6.2.2 (Phase 1 Secondary Endpoint) and Protocol Section 6.2.5 (Phase 2 Secondary Endpoints)
Learn More

UPCC 03424 Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients with Relapsed or Refractory Large B-cell Lymphomas

99 or below
All genders
Please refer to Protocol Section 2 (Study Objectives and Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints) and Protocol Section 9.4 (Primary and Secondary Endpoints). Please refer to Protocol Section 2 (Study Objectives and Endpoints) and Protocol Section 9.4 (Primary and Secondary Endpoints).
Learn More

UPCC 31923: A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in Subjects with Locally Advanced or Metastatic Tumors

99 or below
All genders
The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor receptor tyrosine kinase inhibitor. The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-484 as …
Learn More

BDPI-20-004

99 or below
All genders
For a detailed list of objectives, please refer to Section 3, "Objectives" in the latest protocol. For a detailed list of primary outcomes, please refer to the Section 3.1, "Primary Endpoints" in the latest protocol. For detailed list of secondary outcomes, please refer to Section 3.2, " Secondary Endpoints" in …
Learn More

CONDUIT vs. PEEK Cages

99 or below
All genders
Primary Objective: To determine if CONDUIT and PEEK +rhBMP-2 cages produce similar clinical and radiographic outcomes in patients undergoing direct lateral Interbody fusion Secondary Objective: To determine if CONDUIT and PEEK + rhBMP-2 cages are comparable with regards to cost The primary study endpoint will be the difference in fusion …
Learn More

Rapport

99 or below
All genders
All objectives are listed in section 3 of the protocol, but the primary objective is to demonstrate that RAP-219 is effective in reducing frequency of RNS- recorded long episodes in participants with focal onset seizures. The primary endpoint is the change in RNS long episode frequency during the second 4-week …
Learn More

UPCC 21923: A Phase 1 Open-label, Dose-escalation and Cohort Expansion Study of LUNA18 Monotherapy and Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors

99 or below
All genders
Please see the Protocol, Section 2 (Objectives and Endpoints) Please see the Protocol, Section 2.2.1 (Primary Endpoints) Please see the Protocol, Section 2.2.2 (Secondary Endpoints)
Learn More

UPCC 19223 Open-Label Dose-Finding Trial to Explore Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BI 3706674 Given Orally as Monotherapy in Patients with Unresectable Metastatic KRAS Wild Type Amplified Gastric, Oesophageal, and Gastroeso

99 or below
All genders
Please refer to Protocol Section 2.1.1 (Main objectives). Please refer to Protocol Section 2.1.2 (Primary endpoint(s). Please refer to Protocol Section 2.1.4 (Secondary endpoints).
Learn More

UPCC 12023: Autologous Chimeric Antigen Receptor Engineered T Cell Immunotherapy for Desensitization in Patients Awaiting Kidney Transplantation

99 or below
All genders
Please refer to Protocol Section 2 (Study Hypothesis/Objectives). Please refer to Protocol Section 3.5 (Primary Endpoints). Please refer to Protocol Section 3.6 (Secondary Endpoints).
Learn More

UPCC 29424 Safety and Efficacy of Dual Menin and FLT3 Inhibition in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia Containing a Concurrent MLL-Rearrangement or NPM1 Mutation: A Phase 1 (Ph1) Study of SNDX-5613 + Gilteritinib

99 or below
All genders
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2.1 (Primary Endpoints). Please refer to Protocol Section 2.2 (Secondary Endpoints)
Learn More
21 - 30 of 66